Arcutis exec Robert Lisicki holds 145,000 options

Both equity awards are subject to continued service, with RSUs vesting annually and options vesting monthly.

Available on EDGAR 11/04/2026 - 06:39 PM EST Accepted by SEC EDGAR 11/04/2026 - 06:38 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. reported that Robert Lisicki, EVP, Chief Commercial Officer, directly held a 55,000-share common-stock position represented by RSUs and options covering 145,000 common shares as of November 4, 2026. The RSUs vest 25% on each annual anniversary of August 17, 2026, beginning August 17, 2027, subject to continued service. The options vest at 2.0833% of the shares on each monthly anniversary of August 17, 2026, subject to continued service; their exercise price is $25.61 and they expire August 17, 2036.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Lisicki Robert

Role EVP, Chief Commercial Officer

Type	Security	Shares	Price	Value
Holding	Stock Option (right to buy) F2	--	--	--
Holding	Common Stock F1	--	--	--

Holdings: Stock Option (right to buy) — 145,000 contracts (Direct); Common Stock — 55,000 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") that will vest as of 25% of the RSUs on each annual anniversary of August 17, 2026 (the "Vesting Commencement Date"), beginning on August 17, 2027, subject to the Reporting Person's continued service through the vesting date.
2. F2. The options will vest and become exercisable at the rate of 2.0833% of the shares on each monthly anniversary of August 17, 2026, (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Common-stock position represented by RSUs: 55,000 shares Common shares underlying options: 145,000 shares Option exercise price: $25.61 per share +3 more

6 metrics

Common-stock position represented by RSUs 55,000 shares Direct holding as of November 4, 2026

Common shares underlying options 145,000 shares Direct options as of November 4, 2026

Option exercise price $25.61 per share Direct options

RSU vesting rate 25% On each annual anniversary, beginning August 17, 2027

Option vesting rate 2.0833% On each monthly anniversary of August 17, 2026

Option expiration date August 17, 2036 Direct options

Key Terms

RSUs, Vesting Commencement Date, exercisable, Stock Option (right to buy)

4 terms

RSUs financial

"Represents restricted stock units ("RSUs")"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

Vesting Commencement Date financial

"the "Vesting Commencement Date""

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

exercisable financial

"will vest and become exercisable"

Stock Option (right to buy) financial

"Stock Option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ARQT equity holdings did Robert Lisicki report?

Robert Lisicki reported a directly held 55,000-share common-stock position represented by RSUs and options covering 145,000 common shares as of November 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lisicki Robert

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
11/04/2026

3. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	55,000(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(2)	08/17/2036	Common Stock	145,000	$25.61	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that will vest as of 25% of the RSUs on each annual anniversary of August 17, 2026 (the "Vesting Commencement Date"), beginning on August 17, 2027, subject to the Reporting Person's continued service through the vesting date.

2. The options will vest and become exercisable at the rate of 2.0833% of the shares on each monthly anniversary of August 17, 2026, (the "Vesting Commencement Date"), subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

Exhibit List: EX-24 - Power of Attorney.

	/s/ Latha Vairavan, as Attorney-in-Fact for Robert Lisicki	11/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)